Pneumocystis in Patients Over 75 Year

Pneumocystis in Non-HIV Patients Over 75 Years Old: Epidemiological, Diagnostic, Microbiological and Therapeutic Characteristics

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07004127

Acronym

C_PAPY

Enrollment

162

Registered

2025-06-04

Start date

2010-01-01

Completion date

2023-12-31

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis

Brief summary

Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV. Worldwide, the profile of patients affected by this pathology is changing due to two main factors: * The sustainable stabilization of HIV patients. * The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.). There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

75 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient \> or equal to 75 years of age 2. Microbiological diagnosis: * Direct examination with standard stain, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum) And/or * Direct examination with immunofluorescence, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum) * And/or * Positive PCR (BAL, sputum, nasopharyngeal swab or blood) and CT \< 35 3. Absence of HIV infection 4. Hospitalization in French hospitals between 2010 and 2021 Non-inclusion criteria 1\. Opposition of the patient to participate to the study

Design outcomes

Primary

Measure	Time frame	Description
Clinical data	From DAY 0 to end of treatment	description of clinical data
Therapeutic data	From DAY 0 to end of treatment	description of treatment provide to treat pneumocystosis
Biological data	From DAY 0 to end of treatment	Analysis of biological data realized during follow up

Countries

France

Outcome results